<DOC>
	<DOCNO>NCT02997553</DOCNO>
	<brief_summary>This single-center prospective clinical trial evaluate non-inferiority indocyanine green guide sentinel lymph node biopsy compare gold standard Technecium99 guide sentinel lymph node biopsy patient cancer subject surgery . The diagnostic performance tolerance indocyanine green ( ICG ) radio-isotope ( Techniciun99 ) detection sentinel lymph node ass use `` Optonuclear '' probe ( EURORAD S.A. ) .</brief_summary>
	<brief_title>Fluorescence Sentinel Lymph Node Identification Cancer Surgery</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Vulvar Neoplasms</mesh_term>
	<criteria>age &gt; 18 year cancer histologically prove patient eligible sentinel node detection first surgical treatment contraceptive method men woman childbearing age sign informed consent form patient affiliate social security system neoadjuvant chemotherapy hormone therapy adenopathy ( ) clinically suspicious positively cytopenic woman pregnant breastfeeding associate pathology may prevent patient receive indocyanine green ongoing participation another clinical trial investigational drug patient deprive liberty supervision impossibility undergo medical followup trial geographical , social psychological reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Indocyanine green ( ICG )</keyword>
	<keyword>Sentinel lymph node biopsy</keyword>
	<keyword>Technetium99</keyword>
	<keyword>Tumors</keyword>
	<keyword>Optonuclear probe</keyword>
	<keyword>Surgery</keyword>
</DOC>